Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3)
Based on 1 Customer Validation
Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a mouse-derived IgG2a κ type antibody agonist, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a chimeric antibody of the original LOB12.3 antibody (HY-P990809). Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) contains the LALA-PG mutation region. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease.
For research use only. We do not sell to patients.
- Purity : 98.44%
- Molecular Weight:145.96 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Mouse IgG2a (LALA-PG)
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
4-1BB/CD137
Gene ID
Accession
XP_850336.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo activation of 4-1BB
Verified Bioactivity
-
Immobilized Mouse CD137 Protein, His Tag can bind Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3). The EC50 for this effect is 68.1 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (230 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)